Select publications

Altundag O et al. Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: Downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncogenes. Med Hypotheses 2004;63(2):277-80. Abstract

Baselga J et al. Future options with trastuzumab for primary systemic and adjuvant therapy. Semin Oncol 2004;31(5 Suppl 10):51-7. Abstract

De Laurentiis M et al. Targeting HER2 as a therapeutic strategy for breast cancer: A paradigmatic shift of drug development in oncology. Ann Oncol 2005;16(Suppl 4):iv7-iv13. Abstract

Emens LA. Trastuzumab: Targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer. Am J Ther 2005;12(3):243-53. Abstract

Gasparini G et al. Therapy of breast cancer with molecular targeting agents. Ann Oncol 2005;16 (Suppl 4):iv28-iv36. Abstract

Hampton T. Monoclonal antibody therapies shine in breast cancer clinical trials. JAMA 2005;293(24):2985-9. No abstract available

Hortobagyi GN. Opportunities and challenges in the development of targeted therapies. Semin Oncol 2004;31(1 Suppl 3):21-7. Abstract

Montemurro F, Aglietta M. Incorporating trastuzumab into the neoadjuvant treatment of HER2-overexpressing breast cancer. Clin Breast Cancer 2005;6(1):77-80. Abstract

Pegram MD et al. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004;96(10):739-49. Abstract

Perez EA et al. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. J Clin Oncol 2004;22(18):3700-4. Abstract

Perez EA et al. HER2 testing by local, central, and reference laboratories in the NCCTG N9831 Intergroup Adjuvant Trial. Proc ASCO 2004;Abstract 567.

Perez EA et al. Interim cardiac safety analysis of NCCTG N9831 Intergroup adjuvant trastuzumab trial. Proc ASCO 2005;Abstract 556.

Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004;22(2):322-9. Abstract

Piccart-Gebhart MJ. First results of the HERA trial. Presentation. ASCO 2005. No abstract available

Romond EH et al. Doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab as adjuvant therapy for patients with HER-2 positive operable breast cancer — Combined analysis of NSABP-B31/NCCTG-N9831. Presentation. ASCO 2005. No abstract available

Sledge GW Jr. HERe-2 stay: The continuing importance of translational research in breast cancer. J Natl Cancer Inst 2004;96(10):725-7. No abstract available

Theodoulou M, Seidman AD. Cardiac effects of adjuvant therapy for early breast cancer. Semin Oncol 2003;30(6):730-9. Abstract

Lottner C et al. Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer. J Pathol 2005;205(5):577-84. Abstract

Rueckert S et al. A monoclonal antibody as an effective therapeutic agent in breast cancer: Trastuzumab. Expert Opin Biol Ther 2005;5(6):853-66. Abstract

Youssef G, Links M. The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. Am J Cardiovasc Drugs 2005;5(4):233-43. Abstract